Fedratinib
CAS 936091-26-8
Fedratinib (CAS 936091-26-8) is a pharmaceutical compound with 80 bioactivity targets and 20 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme |
Kd | 5.37 | - | Homo sapiens |
| Platelet-derived growth factor receptor beta Kinase |
Kd | 7.35 | - | Homo sapiens |
| Tyrosine-protein kinase ABL1 Kinase |
Kd | 7.4 | - | Homo sapiens |
| Mast/stem cell growth factor receptor Kit Kinase |
Kd | 7.34 | - | Homo sapiens |
| Epidermal growth factor receptor Kinase |
Kd | 6.24 | - | Homo sapiens |
| Breakpoint cluster region protein Kinase |
Kd | 5.76 | - | Homo sapiens |
| Proto-oncogene tyrosine-protein kinase Src Kinase |
Kd | 7.12 | - | Homo sapiens |
| Tyrosine-protein kinase Lck Kinase |
Kd | 7.14 | - | Homo sapiens |
| Tyrosine-protein kinase Yes Kinase |
Kd | 6.92 | - | Homo sapiens |
| Tyrosine-protein kinase Fyn Kinase |
Kd | 7.42 | - | Homo sapiens |
| Ephrin type-A receptor 2 Kinase |
Kd | 5.36 | - | Homo sapiens |
| Serine/threonine-protein kinase B-raf Kinase |
Kd | 5.03 | - | Homo sapiens |
| Proto-oncogene tyrosine-protein kinase receptor Ret Kinase |
IC50 | 7.32 | - | Homo sapiens |
| Vascular endothelial growth factor receptor 1 Kinase |
Kd | 5.37 | - | Homo sapiens |
| Vascular endothelial growth factor receptor 2 Kinase |
Kd | 5.28 | - | Homo sapiens |
| Vascular endothelial growth factor receptor 3 Kinase |
Kd | 5.7 | - | Homo sapiens |
| Macrophage colony-stimulating factor 1 receptor Kinase |
Kd | 6.21 | - | Homo sapiens |
| Platelet-derived growth factor receptor alpha Kinase |
Kd | 5.57 | - | Homo sapiens |
| Ribosomal protein S6 kinase alpha-3 Kinase |
Kd | 5.09 | - | Homo sapiens |
| Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Kinase |
Kd | 5.8 | - | Homo sapiens |
| Insulin-like growth factor 1 receptor Kinase |
Kd | 5.66 | - | Homo sapiens |
| Myosin light chain kinase, smooth muscle Kinase |
Kd | 6.28 | - | Homo sapiens |
| Insulin receptor Kinase |
Kd | 6.07 | - | Homo sapiens |
| Death-associated protein kinase 3 Kinase |
Kd | 8.92 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type 1 Kinase |
Kd | 5.8 | - | Homo sapiens |
| Mitogen-activated protein kinase 8 Kinase |
Kd | 6.58 | - | Homo sapiens |
| Fibroblast growth factor receptor 3 Kinase |
Kd | 6.44 | - | Homo sapiens |
| Rho-associated protein kinase 1 Kinase |
Kd | 5.68 | - | Homo sapiens |
| Focal adhesion kinase 1 Kinase |
Kd | 7.38 | - | Homo sapiens |
| Tyrosine-protein kinase HCK Kinase |
Kd | 5.68 | - | Homo sapiens |
| Serine/threonine-protein kinase PLK1 Kinase |
Kd | 6.55 | - | Homo sapiens |
| Receptor tyrosine-protein kinase erbB-4 Kinase |
Kd | 5.7 | - | Homo sapiens |
| Mitogen-activated protein kinase 10 Kinase |
Kd | 6.7 | - | Homo sapiens |
| Death-associated protein kinase 2 Kinase |
Kd | 7.54 | - | Homo sapiens |
| High affinity nerve growth factor receptor Kinase |
Kd | 6.08 | - | Homo sapiens |
| Rho-associated protein kinase 2 Kinase |
Kd | 5.66 | - | Homo sapiens |
| Tyrosine-protein kinase SYK Kinase |
Kd | 5.57 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type II subunit delta Kinase |
Kd | 6.23 | - | Homo sapiens |
| Myosin light chain kinase 2, skeletal/cardiac muscle Kinase |
Kd | 5.52 | - | Homo sapiens |
| Tyrosine-protein kinase CSK Kinase |
Kd | 5.23 | - | Homo sapiens |
| Angiopoietin-1 receptor Kinase |
Kd | 5.72 | - | Homo sapiens |
| Ephrin type-A receptor 8 Kinase |
Kd | 5.11 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type II subunit gamma Kinase |
Kd | 6.27 | - | Homo sapiens |
| AP2-associated protein kinase 1 Kinase |
Kd | 7.46 | - | Homo sapiens |
| Serine/threonine-protein kinase MARK2 Kinase |
Kd | 5.51 | - | Homo sapiens |
| Hepatocyte growth factor receptor Kinase |
Kd | 5.36 | - | Homo sapiens |
| Tyrosine-protein kinase Lyn Kinase |
Kd | 6.3 | - | Homo sapiens |
| Cytoplasmic tyrosine-protein kinase BMX Kinase |
Kd | 5.92 | - | Homo sapiens |
| Serine/threonine-protein kinase Nek2 Kinase |
Kd | 5.77 | - | Homo sapiens |
| LIM domain kinase 1 Kinase |
Kd | 6.03 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Vitamin B1 decreased | 31 | 229.859 | 10058740 |
| Vitamin B1 deficiency | 27 | 186.921 | 10047601 |
| Death | 80 | 99.671 | 10011906 |
| Diarrhoea | 77 | 71.943 | 10012735 |
| Full blood count decreased | 24 | 69.301 | 10017413 |
| Splenomegaly | 19 | 57.695 | 10041660 |
| Platelet count decreased | 30 | 43.694 | 10035528 |
| Nausea | 61 | 41.494 | 10028813 |
| Adverse drug reaction | 22 | 40.592 | 10061623 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| Janus kinase 2 JAK2 |
Inhibition | 8.520000457763672 pIC50 | 21106455|18394554 |
| Janus kinase 1 JAK1 |
Inhibition | 7.0 pIC50 | 21106455 |
| Janus kinase 3 JAK3 |
Inhibition | 6.0 pIC50 | 21106455 |
| bromodomain containing 4 BRD4 |
Inhibition | 6.789999961853027 pKd | 24584101 |
| tyrosine kinase 2 TYK2 |
Inhibition | 6.820000171661377 pIC50 | 21106455 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| FEDRATINIB | 2197490 | SU | MTHSPL |
| fedratinib | 2197490 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Fedratinib used for in pharmaceutical contexts?
Fedratinib (CAS 936091-26-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Fedratinib?
Fedratinib has 20 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Vitamin B1 decreased, Vitamin B1 deficiency, Death, Diarrhoea, Full blood count decreased. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Fedratinib also used in cosmetics?
No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Fedratinib.
What clinical phase is Fedratinib in?
No phase 1-4 clinical development badge is rendered for Fedratinib because the matched compound identifier rows do not contain a max-phase value.
What bioactivity targets are documented for Fedratinib?
Fedratinib has 281 bioactivity rows in this page query. Rendered target entries include Ribosyldihydronicotinamide dehydrogenase [quinone], Platelet-derived growth factor receptor beta, Tyrosine-protein kinase ABL1, Mast/stem cell growth factor receptor Kit, Epidermal growth factor receptor.